Candel Therapeutics, Inc.
CADL
$12.17
-$0.43-3.41%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 52.01% | 39.45% | 26.13% | 18.38% | 11.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 99.04% | 68.11% | 44.79% | 15.52% | 2.56% |
| Operating Income | -99.04% | -68.11% | -44.79% | -15.52% | -2.56% |
| Income Before Tax | -299.94% | -37.51% | 30.80% | 56.40% | 55.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -299.94% | -37.51% | 30.80% | 56.40% | 55.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -299.94% | -37.51% | 30.80% | 56.40% | 55.72% |
| EBIT | -99.04% | -68.11% | -44.79% | -15.52% | -2.56% |
| EBITDA | -102.64% | -70.88% | -46.61% | -16.17% | -2.68% |
| EPS Basic | -108.78% | 26.28% | 60.69% | 68.53% | 60.30% |
| Normalized Basic EPS | -109.12% | 26.23% | 60.68% | 68.36% | 60.05% |
| EPS Diluted | -103.89% | 27.17% | 59.77% | 67.60% | 59.34% |
| Normalized Diluted EPS | -105.60% | 26.86% | 60.02% | 67.69% | 59.37% |
| Average Basic Shares Outstanding | 45.26% | 51.17% | 67.20% | 60.26% | 44.94% |
| Average Diluted Shares Outstanding | 41.68% | 46.92% | 70.58% | 63.83% | 48.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |